These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15035219)

  • 1. [Osteoporosis induced by immunosuppressant].
    Fukunaga J; Sugahara T
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():740-3. PubMed ID: 15035219
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoclast differentiation and activation.
    Boyle WJ; Simonet WS; Lacey DL
    Nature; 2003 May; 423(6937):337-42. PubMed ID: 12748652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Merger of bone biology and immunology].
    Suda T; Shima N; Higashio K
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H; Kanatani M; Sugimoto T; Chihara K
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin?].
    Bénard J
    Bull Cancer; 2000 Sep; 87(9):623-4. PubMed ID: 11184451
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between immune and bone cells: new insights with many remaining questions.
    Lorenzo J
    J Clin Invest; 2000 Sep; 106(6):749-52. PubMed ID: 10995785
    [No Abstract]   [Full Text] [Related]  

  • 8. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
    Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
    Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKing the importance of measles virus in Paget's disease.
    Ross FP
    J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
    [No Abstract]   [Full Text] [Related]  

  • 13. Signal transduction pathways regulating osteoclast differentiation and function.
    Tanaka S; Nakamura I; Inoue J; Oda H; Nakamura K
    J Bone Miner Metab; 2003; 21(3):123-33. PubMed ID: 12720046
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
    Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
    Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
    Voskaridou E; Terpos E
    Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
    [No Abstract]   [Full Text] [Related]  

  • 16. [Molecular mechanism of bone metabolism].
    Kotake S; Utagawa N; Suda T; Kamatani N
    Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
    [No Abstract]   [Full Text] [Related]  

  • 17. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoclast stimulating and differentiating factors in human cholesteatoma.
    Hamzei M; Ventriglia G; Hagnia M; Antonopolous A; Bernal-Sprekelsen M; Dazert S; Hildmann H; Sudhoff H
    Laryngoscope; 2003 Mar; 113(3):436-42. PubMed ID: 12616193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
    Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.